Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader–Willi syndrome

• Published in: European journal of endocrinology Vol. 159; no. 4; pp. 381 - 388
• Main Authors: De Waele, Kathleen, Ishkanian, Stacey L, Bogarin, Roberto, Miranda, Charmaine A, Ghatei, Mohammad A, Bloom, Stephen R, Pacaud, Danièle, Chanoine, Jean-Pierre
• Format: Journal Article
• Language: English
• Published: Colchester BioScientifica 01.10.2008; Portland Press
• Subjects: Adolescent; Appetite - drug effects; Biological and medical sciences; Blood Glucose - metabolism; Body Composition - drug effects; Body Height - drug effects; Body Mass Index; Body Weight - drug effects; Child; Clinical Study; Cross-Over Studies; Endocrinopathies; Feeding Behavior - drug effects; Female; Fundamental and applied biological sciences. Psychology; Gallbladder Diseases - diagnostic imaging; Gastrointestinal Agents - administration & dosage; Ghrelin - blood; Homeostasis - drug effects; Humans; Insulin-Like Growth Factor I - metabolism; Male; Medical sciences; Metabolic diseases; Obesity; Octreotide - administration & dosage; Peptide YY - blood; Prader-Willi Syndrome - drug therapy; Prader-Willi Syndrome - metabolism; Ultrasonography; Vertebrates: endocrinology; Endocrinopathy; Appetite; Human; Body weight; Peptide hormone; Diseases of the osteoarticular system; Octreotide; Corporal biometry; Concentration; Neuropeptide; Genetic disease; Appetite stimulant; Treatment; Ghrelin; Analog; Cause; Somatostatin; Behavior; Complex syndrome; Prader Labhart Willi syndrome; Endocrinology
• ISSN: 0804-4643; 1479-683X; 1479-683X
• DOI: 10.1530/EJE-08-0462

ObjectiveGhrelin is secreted primarily by the stomach and circulates as both acylated and desacyl ghrelin. Acylated (but not desacyl) ghrelin stimulates appetite. Both concentrations are elevated in Prader–Willi syndrome (PWS), suggesting that ghrelin may contribute to hyperphagia and overweight in...